196 related articles for article (PubMed ID: 18695251)
1. AIMP2/p38, the scaffold for the multi-tRNA synthetase complex, responds to genotoxic stresses via p53.
Han JM; Park BJ; Park SG; Oh YS; Choi SJ; Lee SW; Hwang SK; Chang SH; Cho MH; Kim S
Proc Natl Acad Sci U S A; 2008 Aug; 105(32):11206-11. PubMed ID: 18695251
[TBL] [Abstract][Full Text] [Related]
2. Cancer-associated splicing variant of tumor suppressor AIMP2/p38: pathological implication in tumorigenesis.
Choi JW; Kim DG; Lee AE; Kim HR; Lee JY; Kwon NH; Shin YK; Hwang SK; Chang SH; Cho MH; Choi YL; Kim J; Oh SH; Kim B; Kim SY; Jeon HS; Park JY; Kang HP; Park BJ; Han JM; Kim S
PLoS Genet; 2011 Mar; 7(3):e1001351. PubMed ID: 21483803
[TBL] [Abstract][Full Text] [Related]
3. Retractile lysyl-tRNA synthetase-AIMP2 assembly in the human multi-aminoacyl-tRNA synthetase complex.
Hei Z; Wu S; Liu Z; Wang J; Fang P
J Biol Chem; 2019 Mar; 294(13):4775-4783. PubMed ID: 30733335
[TBL] [Abstract][Full Text] [Related]
4. Stabilization and activation of p53 induced by Cdk5 contributes to neuronal cell death.
Lee JH; Kim HS; Lee SJ; Kim KT
J Cell Sci; 2007 Jul; 120(Pt 13):2259-71. PubMed ID: 17591690
[TBL] [Abstract][Full Text] [Related]
5. Golgi-SNARE GS28 potentiates cisplatin-induced apoptosis by forming GS28-MDM2-p53 complexes and by preventing the ubiquitination and degradation of p53.
Sun NK; Huang SL; Chien KY; Chao CC
Biochem J; 2012 Jun; 444(2):303-14. PubMed ID: 22397410
[TBL] [Abstract][Full Text] [Related]
6. Multidirectional tumor-suppressive activity of AIMP2/p38 and the enhanced susceptibility of AIMP2 heterozygous mice to carcinogenesis.
Choi JW; Um JY; Kundu JK; Surh YJ; Kim S
Carcinogenesis; 2009 Sep; 30(9):1638-44. PubMed ID: 19622630
[TBL] [Abstract][Full Text] [Related]
7. The RASSF6 tumor suppressor protein regulates apoptosis and the cell cycle via MDM2 protein and p53 protein.
Iwasa H; Kudo T; Maimaiti S; Ikeda M; Maruyama J; Nakagawa K; Hata Y
J Biol Chem; 2013 Oct; 288(42):30320-30329. PubMed ID: 24003224
[TBL] [Abstract][Full Text] [Related]
8. JTV1 co-activates FBP to induce USP29 transcription and stabilize p53 in response to oxidative stress.
Liu J; Chung HJ; Vogt M; Jin Y; Malide D; He L; Dundr M; Levens D
EMBO J; 2011 Mar; 30(5):846-58. PubMed ID: 21285945
[TBL] [Abstract][Full Text] [Related]
9. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic Mutation of AIMP2/p38 Inhibits Its Tumor-Suppressive Interaction with Smurf2.
Kim DG; Lee JY; Lee JH; Cho HY; Kang BS; Jang SY; Kim MH; Guo M; Han JM; Kim SJ; Kim S
Cancer Res; 2016 Jun; 76(11):3422-36. PubMed ID: 27197155
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer Cells.
Carrillo AM; Hicks M; Khabele D; Eischen CM
Mol Cancer Res; 2015 Aug; 13(8):1197-205. PubMed ID: 25964101
[TBL] [Abstract][Full Text] [Related]
12. SIRT7-dependent deacetylation of NPM promotes p53 stabilization following UV-induced genotoxic stress.
Ianni A; Kumari P; Tarighi S; Simonet NG; Popescu D; Guenther S; Hölper S; Schmidt A; Smolka C; Yue S; Krüger M; Fiorillo C; Vaquero A; Bober E; Braun T
Proc Natl Acad Sci U S A; 2021 Feb; 118(5):. PubMed ID: 33495326
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill.
Xie X; He G; Siddik ZH
Mol Pharmacol; 2020 Apr; 97(4):237-249. PubMed ID: 32063580
[TBL] [Abstract][Full Text] [Related]
14. The deubiquitinating enzyme USP24 is a regulator of the UV damage response.
Zhang L; Nemzow L; Chen H; Lubin A; Rong X; Sun Z; Harris TK; Gong F
Cell Rep; 2015 Jan; 10(2):140-7. PubMed ID: 25578727
[TBL] [Abstract][Full Text] [Related]
15. Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma.
Stühmer T; Chatterjee M; Hildebrandt M; Herrmann P; Gollasch H; Gerecke C; Theurich S; Cigliano L; Manz RA; Daniel PT; Bommert K; Vassilev LT; Bargou RC
Blood; 2005 Nov; 106(10):3609-17. PubMed ID: 16081689
[TBL] [Abstract][Full Text] [Related]
16. The p53-Mdm2 feedback loop protects against DNA damage by inhibiting p53 activity but is dispensable for p53 stability, development, and longevity.
Pant V; Xiong S; Jackson JG; Post SM; Abbas HA; Quintás-Cardama A; Hamir AN; Lozano G
Genes Dev; 2013 Sep; 27(17):1857-67. PubMed ID: 23973961
[TBL] [Abstract][Full Text] [Related]
17. PICT-1 is a key nucleolar sensor in DNA damage response signaling that regulates apoptosis through the RPL11-MDM2-p53 pathway.
Chen H; Han L; Tsai H; Wang Z; Wu Y; Duo Y; Cao W; Chen L; Tan Z; Xu N; Huang X; Zhuang J; Huang L
Oncotarget; 2016 Dec; 7(50):83241-83257. PubMed ID: 27829214
[TBL] [Abstract][Full Text] [Related]
18. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of MDM2 stabilizes p53 by inhibiting p53 ubiquitination in response to specific alkylating agents.
Inoue T; Geyer RK; Yu ZK; Maki CG
FEBS Lett; 2001 Feb; 490(3):196-201. PubMed ID: 11223035
[TBL] [Abstract][Full Text] [Related]
20. Inability of p53-reactivating compounds Nutlin-3 and RITA to overcome p53 resistance in tumor cells deficient in p53Ser46 phosphorylation.
Ma T; Yamada S; Ichwan SJ; Iseki S; Ohtani K; Otsu M; Ikeda MA
Biochem Biophys Res Commun; 2012 Jan; 417(3):931-7. PubMed ID: 22166212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
